Alexander C J van Akkooi
Overview
Explore the profile of Alexander C J van Akkooi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
4497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Novis E, van Akkooi A
Curr Oncol Rep
. 2024 Jun;
26(8):924-933.
PMID: 38842606
Purpose Of Review: The management of cutaneous melanoma has rapidly progressed over the past decade following the introduction of effective systemic therapies. Given the large number of recent clinical trials...
12.
Blank C, Lucas M, Scolyer R, van de Wiel B, Menzies A, Lopez-Yurda M, et al.
N Engl J Med
. 2024 Jun;
391(18):1696-1708.
PMID: 38828984
Background: In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. Methods: In this phase 3 trial, we randomly assigned...
13.
Zijlker L, Chen H, Spillane A, Gonzalez M, Pennington T, Menzies A, et al.
Ann Surg Oncol
. 2024 May;
31(8):5324-5330.
PMID: 38762644
Background: Neoadjuvant systemic therapy (NAST) for patients with stage III melanoma achieves high major pathologic response rates and high recurrence-free survival rates. This study aimed to determine how NAST with...
14.
Versluis J, Blankenstein S, Dimitriadis P, Wilmott J, Elens R, Blokx W, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38677880
Background: A substantial proportion of patients with macroscopic stage III melanoma do not benefit sufficiently from adjuvant anti-PD-1 therapy, as they either recur despite therapy or would never have recurred....
15.
Kuijpers A, van Akkooi A
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38610925
Melanoma treatment is leading the neo-adjuvant systemic (NAS) therapy field. It is hypothesized that having the entire tumor in situ, with all of the heterogeneous tumor antigens, allows the patient's...
16.
Stassen R, Maas C, van der Veldt A, Lo S, Saw R, Varey A, et al.
Lancet Oncol
. 2024 Mar;
25(4):509-517.
PMID: 38547894
Background: The introduction of adjuvant systemic treatment for patients with high-risk melanomas necessitates accurate staging of disease. However, inconsistencies in outcomes exist between disease stages as defined by the American...
17.
Holmberg C, Zijlker L, Katsarelias D, Huibers A, Wouters M, Schrage Y, et al.
Eur J Surg Oncol
. 2024 Mar;
50(6):108265.
PMID: 38493679
Objective: ILP has shown to achieve high response rates in patients with melanoma ITM. Possibly there is a synergistic mechanism of action of ILP and anti-PD1. The aim of this...
18.
Kennedy O, Glassee N, Kicinski M, Blank C, Long G, Atkinson V, et al.
Eur J Cancer
. 2024 Feb;
201:113585.
PMID: 38402687
Background: Pain is common in patients with cancer. The World Health Organisation recommends paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) for mild pain and combined with other agents for moderate/severe pain....
19.
Laeijendecker A, El Sharouni M, Stathonikos N, Spoto C, van de Wiel B, Eijken E, et al.
J Clin Pathol
. 2024 Feb;
77(6):372-377.
PMID: 38378246
Identification of sentinel node (SN) metastases can set the adjuvant systemic therapy indication for stage III melanoma patients. For stage IIIA patients, a 1.0 mm threshold for the largest SN...
20.
Eggermont A, Kicinski M, Blank C, Mandala M, Long G, Atkinson V, et al.
NEJM Evid
. 2024 Feb;
1(11):EVIDoa2200214.
PMID: 38319852
BACKGROUND: In the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence- and distant metastasis-free survival than placebo in patients...